U.S. Stem Cell, Inc. Stock

USRM

US90350U1007

Biotechnology & Medical Research

Market Closed - OTC Markets 15:56:45 2026-06-01 EDT			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-.--%	+9,900.00%

23-04-14	U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-04-13	U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	CI

Valuation: U.S. Stem Cell, Inc.

Market Cap	661 572.76 540.51 490.36 919.86 63.35K 926.52 6.46K 2.49K 32.14K 2.48K 2.43K 102K	P/E 2021	-0.84x	P/E 2022	-0.99x
Enterprise Value	10.08M 8.73M 8.24M 7.48M 14.03M 966M 14.13M 98.44M 37.93M 490M 37.86M 37.02M 1.56B	EV / Sales 2021	59.5x	EV / Sales 2022	160x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Latest news: U.S. Stem Cell, Inc.

23-04-14	U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-04-13	U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	CI
22-11-09	U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-05-23	U.S. Stem Cell, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
22-03-31	U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
22-03-30	U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	CI
22-03-09	U.S. Stem Cell, Inc. Announces Management Changes	CI
21-11-09	U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
21-08-12	U.S. Stem Cell, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	CI
21-07-15	U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	CI
21-07-15	U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	CI
20-12-30	U.S. Stem Cell, Inc.'s Equity Buyback announced on January 16, 2015, has expired.	CI
19-11-06	U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI

More news

Press Releases: U.S. Stem Cell, Inc.

23-04-14	U.S. STEM CELL, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
22-11-09	NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	AQ
22-07-08	U.S. STEM CELL, INC. - 10-K/A - Management's Discussion and Analysis of Financial Condition and Results of Operations	AQ
22-05-23	NOTE 2 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	AQ
22-03-31	U.S. STEM CELL, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ

More press releases

Managers and Directors: U.S. Stem Cell, Inc.

Manager	Title	Age	Since
Miguel Tomás CEO	Chief Executive Officer	60	2010-06-23

Director	Title	Age	Since
William Murphy CHM	Chairman	-	2010-11-01
Miguel Tomás BRD	Director/Board Member	60	2011-08-16
Sheldon Anderson BRD	Director/Board Member	75	2013-08-27

More insiders

U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The myoblast cells to be injected are gene-modified prior to injection by an adenovirus vector so that they will release extra quantities of stromal derived factor - 1 or SDF-1 protein. The Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
USRM Stock

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!

1 month	0		0
Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.01
10 years	0		0.18

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
4/25/22	Greg Knutson	Free	Director	2,500,000	0.5198%
4/25/22	Northstar Biotech Group LLC	Other	Company	0	0%	-
3/18/22	Greg Knutson	Free	Director	50,000,000	10.3959%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
U.S. STEM CELL, INC.	-.--%	-.--%	-.--%	-50.00%	66.15K
WUXI APPTEC CO., LTD.	+5.04%	+3.66%	+50.62%	+103.77%	70.24B
ARGENX SE	+1.64%	-0.18%	+34.67%	+76.81%	62.63B
INSMED INCORPORATED	-3.18%	-0.78%	-14.14%	+369.82%	27.36B
WUXI BIOLOGICS (CAYMAN) INC.	-0.61%	-0.77%	+25.95%	+11.44%	25.71B
BIONTECH SE	+2.20%	-4.72%	+2.19%	-13.14%	24.83B
GENMAB A/S	+1.15%	-1.17%	+17.56%	-21.92%	19.52B
PHARMAESSENTIA CORPORATION	-7.03%	-10.19%	+161.91%	+303.00%	15.51B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-4.20%	-5.12%	-9.04%	+486.08%	14.66B
SUMMIT THERAPEUTICS INC.	+4.96%	+4.63%	-2.75%	+864.40%	14.69B
Average	+0.05%	-1.64%	+26.70%	+213.03%	27.52B
Weighted average by Cap.	+1.25%	-0.80%	+31.77%	+168.22%

	2021	2022
Net sales	201K 174K 164K 149K 279K 19.24M 281K 1.96M 755K 9.76M 754K 737K 31.03M	82.05K 71.1K 67.09K 60.87K 114K 7.86M 115K 801K 309K 3.99M 308K 301K 12.68M
Net income	-3.29M -2.85M -2.69M -2.44M -4.57M -315M -4.61M -32.1M -12.37M -160M -12.35M -12.08M -508M	-2.86M -2.48M -2.34M -2.12M -3.98M -274M -4.01M -27.91M -10.76M -139M -10.73M -10.5M -442M
Net Debt	8.93M 7.74M 7.3M 6.62M 12.42M 856M 12.51M 87.19M 33.6M 434M 33.53M 32.79M 1.38B	10.08M 8.73M 8.24M 7.48M 14.03M 966M 14.13M 98.43M 37.93M 490M 37.86M 37.02M 1.56B

U.S. Stem Cell, Inc. Stock

Stocks

USRM

US90350U1007

Biotechnology & Medical Research

Valuation: U.S. Stem Cell, Inc.

Chart: U.S. Stem Cell, Inc.

Latest news: U.S. Stem Cell, Inc.

Press Releases: U.S. Stem Cell, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: U.S. Stem Cell, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile